Latest / Finance TL;DR Daily / Uber's $14.8B Delivery Hero Deal Shakes Up Global Food Delivery
Transcript
- Uber's $14.8B Delivery Hero Deal Shakes Up Global Food Delivery 2026-07-16 Welcome to Finance TL;DR Daily, the podcast where we break down the biggest stories in finance. It's Thursday, July 16th, and today's headline is a genuine megadeal: Uber is buying German food delivery giant Delivery Hero for nearly $15 billion, in a move that would create the biggest delivery platform on the planet outside of China. Here's what's moving today. Let's start with that Uber deal, because the numbers are enormous. Uber has signed a business combination agreement to launch a takeover offer for Delivery Hero at €41.50 per share in cash. That values the company at $14.8 billion, though once you account for Uber's existing stake, the adjusted price tag comes in closer to $13.7 billion. The combined company would operate across 99 markets worldwide. Now, regulators were always going to have questions about a deal this big, so the companies got ahead of it. Delivery Hero has separately agreed to sell off its operations in 14 overlapping European markets to an investment firm called SSW Partners, for roughly $1.6 billion, specifically to head off antitrust concerns. Major shareholder Prosus, which holds 17% of Delivery Hero, has already committed to tendering its shares, and the whole thing is expected to close in the second half of 2027. Why is Uber doing this? In its announcement, the company pointed to a simple stat: customers who use both Uber's ride-hailing and delivery services spend three times as much as customers who only use one. This is Uber betting big on cross-selling at global scale, and it's a clear signal that consolidation in food delivery isn't slowing down — if anything, it's entering a new, much bigger phase. Switching gears to trade policy, because there's a major tariff story breaking today. The U.S. is imposing a 25% tariff on most imports from Brazil, effective July 22nd. This follows a yearlong investigation under Section 301 of the Trade Act, which found that Brazil engaged in what the U.S. calls unreasonable trade practices — spanning digital trade rules, weak anti-corruption enforcement, and illegal deforestation. Brazil is the world's tenth-largest economy, so this isn't a minor trading partner. The administration did carve out some exemptions to limit the pain for American consumers — coffee, beef, orange juice, energy products, and aerospace components are all spared. U.S. Trade Representative Jamieson Greer defended the move, saying, quote, "Brazil's unfair trading practices have prevented U.S. workers and producers from accessing this important market with over 210 million consumers." Brazilian President Luiz Inácio Lula da Silva pushed back hard, calling the tariffs a, quote, "lamentable milestone" in relations between the two countries, and he's promising retaliation along with a formal challenge at the World Trade Organization. What matters here for markets is the pattern: another unilateral tariff action against a major economy, which raises the odds of tit-for-tat measures and adds a fresh layer of uncertainty to global supply chains. Now to some genuinely good news out of the healthcare sector. UnitedHealth Group just posted a blowout second quarter. The company reported consolidated revenues of $112 billion and adjusted earnings of $6.38 per share — miles ahead of the $4.85 per share Wall Street analysts were expecting. The key to the beat was medical costs: UnitedHealth's medical care ratio, essentially the share of premium revenue spent on patient care, improved to 86.7%, down from 89.4% a year earlier. Lower costs plus strong showings from both its UnitedHealthcare and Optum divisions added up to a very good quarter. On the back of it, the company raised its full-year adjusted earnings guidance to a range of $19.50 to $20.00 per share, and lifted its operating cash flow forecast to about $24 billion. CEO Stephen Hemsley credited the results to, quote, work to "simplify how we operate, improve both affordability and the health care experience for patients and care providers." The market reaction was immediate — UnitedHealth shares jumped more than 7% in early trading, and given the company's size, that kind of move tends to give a lift to the broader market and set a tone for how investors are viewing the health insurance sector heading into the back half of the year. Last up, a story that shows just how mainstream psychedelic medicine has become. Eli Lilly announced it's acquiring AtaiBeckley, a psychedelic drug developer, in a deal worth up to $3.8 billion. The structure here is worth breaking down: Lilly is paying $6.75 per share upfront in cash, which works out to about $2.8 billion, and that's a 40% premium over AtaiBeckley's 30-day average share price. On top of that, shareholders can collect up to another $2.50 per share through contingent value rights if certain clinical and regulatory milestones are hit — potentially adding another $1 billion to the total. What Lilly is really buying is the pipeline, led by a drug called BPL-003, a fast-acting nasal formulation of 5-MeO-DMT that's already in Phase 3 trials for treatment-resistant depression. AtaiBeckley's co-founder and CEO, Srinivas Rao, framed the mission this way: quote, "we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms." For the broader industry, this deal is a strong signal that big pharmaceutical companies are no longer treating psychedelic-based therapies as fringe science — they're treating them as a serious, competitive front in the fight for the massive treatment-resistant depression market. So, to wrap today: a $14.8 billion delivery megadeal, fresh tariffs rattling U.S.-Brazil trade relations, a blowout quarter lifting UnitedHealth and the broader market, and Eli Lilly making a multi-billion dollar bet on psychedelic medicine. This has been Finance TL;DR Daily. We'll see you tomorrow.